▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1242 by analyst upside · 2026-06-27
CTNM
Contineum Therapeutics, Inc.
Healthcare · Market Cap $531M · P/E 0x
ANALYST PRICE TARGET
+57.4%
implied upside to consensus target
Current Price $14.19
Consensus Target $22.33
Bull Target $28.0
Bear Target $16.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
1
Sell
0
52-Week Low $3.72
52-Week High $16.33
YTD Return +24.6%
FUNDAMENTALS
Market Cap $531M
P/E Ratio (TTM) N/A
Forward P/E -7.8x
EPS (TTM) $-1.94
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.72
52-Week High $16.33
Current Price $14.19
Bear Target $16.0
Bull Target $28.0
● Now $14.19 ● Target $22.33
TRADING DATA
Avg Volume 232K
YTD Return +24.6%
Analyst Count 6
Consensus Buy
Upside to Target +57.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Contineum Therapeutics, Inc. (CTNM) is currently trading at $14.19 with a Wall Street consensus price target of $22.33, implying potential upside of 57.4% over the next 12 months. 6 analysts currently cover CTNM, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $28.0, while the most cautious has a target of $16.0.

CTNM operates in the Healthcare sector with a market capitalisation of $531M. The stock is up 24.6% year-to-date and is currently trading near the upper end of its 52-week range of $3.72 – $16.33.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MDXG +65.4%
MiMedx Group, Inc.
$585M · P/E 19.6x · Buy
IRWD +47.7%
Ironwood Pharmaceuticals, Inc.
$680M · P/E 6.3x · Buy
BVS +51.3%
Bioventus Inc.
$663M · P/E 23.9x · Buy
RIGL +40.1%
Rigel Pharmaceuticals, Inc.
$716M · P/E 2.0x · Buy
KMDA +79.1%
Kamada Ltd.
$419M · P/E 20.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CTNM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-05-14 Building track record
Baird — Reiterated
Outperform → Outperform 2026-03-06 Building track record
Morgan Stanley ↓ Downgrade
Overweight → Equal-Weight 2026-01-08 Building track record
Baird — Reiterated
Outperform → Outperform 2025-11-24 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2025-11-21 Building track record
Leerink Partners ● Initiated
Outperform 2025-09-25 29% win rate (7 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2025-08-18 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2025-05-19 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
15/30
Consensus clarity
13/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →